Genetic developmental and epileptic encephalopathies in adulthood: Gaps in evidence and care.
10 affiliations
- 1Department of Neurology, Beaumont Hospital, Dublin, Ireland.
- 2Blackrock Clinic, Dublin, Ireland.
- 3School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
- 4UCD Centre for Disability Studies, UCD School of Psychology, Dublin, Ireland.
- 5Adult Genetic Epilepsy Program (AGE), University of Toronto, Toronto, Ontario, Canada.
- 6Krembil Brain Institute, Toronto Western Hospital, UHN, University of Toronto, Toronto, Ontario, Canada.
- 7Division of Neurology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- 8FutureNeuro Research Ireland Centre for Translational Brain Science, Dublin, Ireland.
- 9Dublin Neurological Institute, Mater Misericordiae University Hospital, Dublin, Ireland.
- 10School of Medicine, University College Dublin, Dublin, Ireland.
Abstract
Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of the most severe epilepsies, characterized by seizure onset and neurodevelopmental delay in infancy or childhood, often with additional neurological and systemic comorbidities. Up to 50% of cases have an identifiable genetic cause, with structural etiologies representing a small minority. Although associated with early mortality, many individuals now live into adulthood. Over the past 15 years, advances in genetic diagnosis and understanding of disease mechanisms have created realistic prospects of precision therapies, including gene and RNA therapies. The adult phase of DEEs remains poorly characterized, with limited observational evidence. Adults with DEEs are underrepresented in the literature and often excluded from clinical trials, despite ongoing drug-resistant epilepsy, evolving neurodevelopmental disability, and an increasing burden of comorbidities with age. In this narrative review, we discuss important aspects of care for adults with genetic DEEs, including genetic testing, comorbidities and treatment. We also review available natural history studies, recent clinical trials, and consider how emerging disease-modifying therapies may reshape adult phenotypes and redefine priorities for lifelong care. PLAIN LANGUAGE SUMMARY: Developmental and epileptic encephalopathies (DEEs) are a group of rare diseases that are often caused by genetic changes. They usually begin in childhood with severe epilepsy but can also affect learning, development, and overall health throughout life. This review examines the healthcare needs of adults with DEEs, highlights areas where more research is needed, and explores how new treatments may improve health and quality of life across the lifespan.
Related
- Caregiver perceptions of telemedicine in developmental and epileptic encephalopathies: a nationwide Spanish survey
- Beyond seizures: the hidden burden of developmental epileptic encephalopathies
- Clinic-to-Mechanism: Unraveling in-depth molecular dysfunctions caused by a GluN2B C-Terminal deletion in developmental and epileptic encephalopathies
- Precision Therapeutics for Monogenic Epilepsies: From Molecular Mechanisms to Disease Modification in Developmental and Epileptic Encephalopathies and Neurodevelopmental Disorders with Epilepsy
- Functional characterization and pharmacochaperone rescue of a novel SLC6A1 variant associated with developmental epileptic encephalopathies
BibTeX
@article{dudley2026genetic,
title = {{Genetic developmental and epileptic encephalopathies in adulthood: Gaps in evidence and care.}},
author = {Alex M Dudley and Peter Widdess-Walsh and Christine Linehan and Danielle M Andrade and Norman Delanty and Patrick B Moloney},
journal = {Epilepsia open},
year = {2026},
month = oct,
doi = {10.1002/epi4.70359},
url = {https://europepmc.org/article/MED/42873555},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Genetic developmental and epileptic encephalopathies in adulthood: Gaps in evidence and care.
AU - Alex M Dudley
AU - Peter Widdess-Walsh
AU - Christine Linehan
AU - Danielle M Andrade
AU - Norman Delanty
AU - Patrick B Moloney
PY - 2026
DA - 2026/10/14
JO - Epilepsia open
DO - 10.1002/epi4.70359
UR - https://europepmc.org/article/MED/42873555
AB - Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of the most severe epilepsies, characterized by seizure onset and neurodevelopmental delay in infancy or childhood, often with additional neurological and systemic comorbidities. Up to 50% of cases have an identifiable genetic cause, with structural etiologies representing a small minority. Although associated with early mortality, many individuals now live into adulthood. Over the past 15 years, advances in genetic diagnosis and understanding of disease mechanisms have created realistic prospects of precision therapies, including gene and RNA therapies. The adult phase of DEEs remains poorly characterized, with limited observational evidence. Adults with DEEs are underrepresented in the literature and often excluded from clinical trials, despite ongoing drug-resistant epilepsy, evolving neurodevelopmental disability, and an increasing burden of comorbidities with age. In this narrative review, we discuss important aspects of care for adults with genetic DEEs, including genetic testing, comorbidities and treatment. We also review available natural history studies, recent clinical trials, and consider how emerging disease-modifying therapies may reshape adult phenotypes and redefine priorities for lifelong care. PLAIN LANGUAGE SUMMARY: Developmental and epileptic encephalopathies (DEEs) are a group of rare diseases that are often caused by genetic changes. They usually begin in childhood with severe epilepsy but can also affect learning, development, and overall health throughout life. This review examines the healthcare needs of adults with DEEs, highlights areas where more research is needed, and explores how new treatments may improve health and quality of life across the lifespan.
SN - 2470-9239
ER -